Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Data unavailable.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 17 Mar 2006 | UBS SECURITIES ASIA LTD. | Bulk | Buy | 4,768,686 | 402.3500 | BSE |
| 17 Mar 2006 | DEUTSCHE INT A.C CROWN CA | Bulk | Sell | 8,218,686 | 402.3500 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 28 Apr 2011 | Dividend - Rs. 2 Per Share | 2.0000 | — |
| 2 Nov 2006 | Interim Dividend-50% | — | 3 Nov 2006 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 17 Jul 2014 | OTHER | Annual General Meeting |
| 25 Apr 2013 | OTHER | Annual General Meeting |
| 26 Apr 2012 | OTHER | Annual General Meeting |
| 29 Apr 2010 | OTHER | Annual General Meeting |
| 20 May 2009 | OTHER | Annual General Meeting |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 31 Mar 2015 | Disclosure under SEBI Takeover Regulations | Sun Pharmaceutical Industries Limited has submitted to the Exchange vide letter dated March 30, 2015 a copy of disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. |
| 25 Mar 2015 | Suspension of trading in equity shares | Members of the Exchange are hereby informed that the trading in equity shares of Ranbaxy Laboratories Limited shall be suspended w.e.f. April 06, 2015 (i.e. closing hours of trading on April 1, 2015) on account of Scheme of Amalgamation with Sun Pharmaceuticals Industries Limited. |
| 25 Mar 2015 | Record Date | Sun Pharmaceuticals Industries Limited has informed the Exchange that the Company has fixed Record Date as April 7, 2015 to determine the names of the shareholders of erstwhile Ranbaxy who would be entitled to receive 8 ( eight) equity shares of Re.1 each of the Company for every 10 (ten) equity shares of Rs.5 each of erstwhile Ranbaxy held and to determine the names of the NCD holders who would be entitled to 1 (One) NCD of Rs.1 lac each of the Company for every 1 (One) NCD of Rs.1 lac each held in erstwhile Ranbaxy pursuant to amalgamation of erstwhile Ranbaxy into the Company. |
| 24 Mar 2015 | Updates | Ranbaxy Laboratories Limited has informed the Exchange regarding "Intimation about the approval received from Reserve Bank of India and Competition Commission of India in respect of the Scheme of Arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd". |
| 9 Mar 2015 | Scheme of Arrangement | Ranbaxy Laboratories Limited has informed the Exchange that the Hon'ble High Court of Punjab & Haryana has orally pronounced the Order on March 9, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories Ltd. with Sun Pharmaceutical Industries Ltd. under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013. Certified true copy of the Order is awaited. |
| 3 Mar 2015 | News Clarification | The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy loses drug pleas in US". The Company has clarified that "Previously Company has informed the Exchange on November 21, 2014 that the Company had filed a complaint against the US FDA in D.C. Federal Court and in the first instance asking the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided, which was denied. Following that determination, the Court ordered the parties in the suit to prepare and file legal briefs addressing Ranbaxy's request for a preliminary injunction and the defendants request for summary judgment on the merits. Prior to the decision by the Court, FDA rescinded our 180 day exclusivity for Esomeprazole magnesium delayed release capsule 20 mg and 40 mg. This was communicated to the Stock Exchanges vide our Statement dated January 27, 2015. The Court has now issued an opinion indicating that it was (i) denying Ranbaxy's request for preliminary injunction and (ii) granting defendants requests for summary judgment on the merits. In effect, the Court's decision upheld the status quo that FDA had created by rescinding Ranbaxy's tentative approvals and forfeiting our 180 day exclusivities on Valganciclovir and Esomeprazole in November, 2014". |
| 2 Mar 2015 | News Clarification | The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy loses drug pleas in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited. |
| 2 Feb 2015 | Press Release | Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated February 2, 2015, titled "Sun Pharma receives US FTC clearance for Ranbaxy acquisition". |
| 28 Jan 2015 | Press Release | Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 28, 2015 titled "Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec'14 Sales Rs.81,778 Mn". |
| 28 Jan 2015 | Financial Result Updates | Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
